Zika Virus (ZIKV) Research Reagents — Antibodies & Recombinant Proteins

Zika virus (ZIKV) is a flavivirus that causes fever, rash, and arthralgia in infected individuals, with severe clinical significance during pregnancy causing microcephaly and congenital Zika syndrome. The virus has a positive-sense single-stranded RNA genome encoding structural proteins including the envelope protein (E) and precursor membrane protein (prM), and non-structural proteins (NS1, NS2A-NS5). The E protein is the primary target for neutralizing antibodies and vaccine development, while NS1 is an important diagnostic marker for acute infection. Diagnostic antibodies and functional reagents are critical for clinical research, vaccine development, maternal serology screening, and antiviral therapeutic studies.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

ZIKV virion structure — E protein dimers and NS1 antigen

Fig. 1 ZIKV structure. E protein dimers form the primary surface lattice; NS1 is secreted during acute infection. Positive-sense RNA genome (~11 kb) packaged within icosahedral-like capsid.

abinScience provides recombinant E protein antigens, NS1 diagnostic antigens, monoclonal and polyclonal antibodies, and validated antibody pairs for ZIKV research. All products manufactured by our parent company AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems. Contact us for vaccine development, maternal serology assays, and neutralization studies.

Key Research Targets

Envelope Protein (E) — E protein is the primary surface antigen (~120 E monomers per virion) and the dominant neutralizing antigen. E-specific neutralizing antibodies provide protective immunity and are the basis of vaccine development. RecombinantE protein (VK740011, VK740012) serves as an immunogen and ELISA coating antigen. InVivoMAb anti-E antibodies (VK740010) support in vivo neutralization studies and passive immunization experiments. E domain-III (DIII)-specific antibodies (VK740023, VK740033) enable epitope-specific neutralization mapping and therapeutic antibody screening.
→ Browse ZIKV E protein products

NS1 Antigen — Early Diagnostic Marker — NS1 is secreted during acute ZIKV infection, providing an excellent biomarker for early diagnosis and differentiation from previous dengue/yellow fever exposure. Recombinant NS1 antigens (VK656011, VK656012) enable rapid diagnostic ELISA development. Anti-NS1 monoclonal and polyclonal antibodies (VK656010, VK656014) are critical for maternal acute infection screening and serological discrimination of primary vs. secondary flavivirus infections.
→ Browse ZIKV NS1 products

Structural Proteins (prM, Capsid C) — Precursor membrane (prM) and capsid (C) proteins are essential for virion maturation and RNA packaging. Recombinant prM and capsid antigens (VK498012, VK629012) support structural virology studies and comparative flavivirus research. Antibodies against these proteins enable detection of immature virions and understanding of viral maturation dynamics.
→ Browse all ZIKV products

Recommended Applications

Vaccine Development & Neutralization Assays
Recombinant ZIKV E protein and domain-III (DIII) antigens are optimal immunogens and ELISA coating antigens for vaccine immunogenicity assessment. InVivoMAb anti-E and anti-DIII antibodies enable in vivo neutralization studies, passive immunization experiments, and functional antibody characterization. Monoclonal antibody panels support epitope-specific neutralization mapping and therapeutic candidate identification.

Maternal Serology Screening & Diagnostic Development
Anti-ZIKV E and NS1 antibody pairs enable sandwich ELISA and rapid diagnostic assay development for acute infection detection and maternal pregnancy serology screening. NS1 antigen detection indicates acute infection risk; E protein serology confirms prior exposure. Ready-to-use assay formats support congenital infection risk assessment and maternal-fetal transmission prevention programs.

References

1. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531-1539.

2. Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951-958.

3. Musso D, Bossin H, Mallet HP, et al. Zika virus in French Polynesia 1966 and 2013–14: insights on the long absence before the recent outbreaks. Euro Surveill. 2014;19(29):20856.

4. Rey FA, Stiasny K, Vaney MC, et al. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 2018;19(2):206-224.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems. Contact us for custom antibody development and assay optimization.